The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer

the impact of oestrogen receptor and HER2 pathways

Dena A. Jerjees, Ola H. Negm, M. Layth Alabdullah, Sameer Mirza, Methaq Alkaabi, Mohamed R. Hameed, Rezvan Abduljabbar, Abir Muftah, Chris C. Nolan, Andrew R. Green, Patrick J. Tighe, Vimla Band, Ian O. Ellis, Emad A. Rakha

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The mammalian target of rapamycin complex 1 (mTORC1) is a downstream of the PI3K/Akt pathway which affects cancer development. mTORC1 has many downstream signalling effectors that can enhance different cellular responses. This study aims to investigate the expression of mTORC1 in breast cancer (BC) and correlate it with key clinicopathological and molecular features of BC especially to proteins related to oestrogen receptor (ER) and HER2 pathways in different BC classes. Moreover, mTORC1 expression was assessed in 6 BC cell lines including ER+ and ER− cell lines with and without HER2 transfection. Immunohistochemistry was used to assess the expression of phospho (p) mTORC1 in a large (n = 1300) annotated BC series prepared as tissue microarray. Reverse phase protein array (RPPA) was used to assess its expression in the different BC cell lines. The expression of p-mTORC1 was cytoplasmic with moderate/high expression noted in 44 % of BC. p-mTORC1 expression was associated with clinicopathological variables characteristic of good prognosis. Positive correlation with ER, ER-related proteins AKT, PI3K and luminal differentiation markers were observed in the whole series and in the ER+HER2− subgroup. Association with HER2 was mainly observed in the ER-negative class. RPPA indicated that p-mTORC1 expression was mainly related to ER expression and with better outcome in the Akt positive tumours. p-mTORC1 is associated with good prognostic features. Its expression is related to ER and ER related proteins in addition to AKT and PI3K. Its relation with HER2 expression is mainly seen in the absence of ER expression.

Original languageEnglish (US)
Pages (from-to)91-103
Number of pages13
JournalBreast Cancer Research and Treatment
Volume150
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

Estrogen Receptors
Breast Neoplasms
Phosphatidylinositol 3-Kinases
Protein Array Analysis
Cell Line
mechanistic target of rapamycin complex 1
Proteins
Differentiation Antigens
Transfection
Neoplasms
Immunohistochemistry

Keywords

  • Breast cancer
  • Immunohistochemistry
  • mTORC1
  • pi3k pathway

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Jerjees, D. A., Negm, O. H., Alabdullah, M. L., Mirza, S., Alkaabi, M., Hameed, M. R., ... Rakha, E. A. (2015). The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer: the impact of oestrogen receptor and HER2 pathways. Breast Cancer Research and Treatment, 150(1), 91-103. https://doi.org/10.1007/s10549-015-3308-4

The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer : the impact of oestrogen receptor and HER2 pathways. / Jerjees, Dena A.; Negm, Ola H.; Alabdullah, M. Layth; Mirza, Sameer; Alkaabi, Methaq; Hameed, Mohamed R.; Abduljabbar, Rezvan; Muftah, Abir; Nolan, Chris C.; Green, Andrew R.; Tighe, Patrick J.; Band, Vimla; Ellis, Ian O.; Rakha, Emad A.

In: Breast Cancer Research and Treatment, Vol. 150, No. 1, 01.01.2015, p. 91-103.

Research output: Contribution to journalArticle

Jerjees, DA, Negm, OH, Alabdullah, ML, Mirza, S, Alkaabi, M, Hameed, MR, Abduljabbar, R, Muftah, A, Nolan, CC, Green, AR, Tighe, PJ, Band, V, Ellis, IO & Rakha, EA 2015, 'The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer: the impact of oestrogen receptor and HER2 pathways', Breast Cancer Research and Treatment, vol. 150, no. 1, pp. 91-103. https://doi.org/10.1007/s10549-015-3308-4
Jerjees, Dena A. ; Negm, Ola H. ; Alabdullah, M. Layth ; Mirza, Sameer ; Alkaabi, Methaq ; Hameed, Mohamed R. ; Abduljabbar, Rezvan ; Muftah, Abir ; Nolan, Chris C. ; Green, Andrew R. ; Tighe, Patrick J. ; Band, Vimla ; Ellis, Ian O. ; Rakha, Emad A. / The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer : the impact of oestrogen receptor and HER2 pathways. In: Breast Cancer Research and Treatment. 2015 ; Vol. 150, No. 1. pp. 91-103.
@article{823dcc7f8a5e437fb29a318479b1ce1c,
title = "The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer: the impact of oestrogen receptor and HER2 pathways",
abstract = "The mammalian target of rapamycin complex 1 (mTORC1) is a downstream of the PI3K/Akt pathway which affects cancer development. mTORC1 has many downstream signalling effectors that can enhance different cellular responses. This study aims to investigate the expression of mTORC1 in breast cancer (BC) and correlate it with key clinicopathological and molecular features of BC especially to proteins related to oestrogen receptor (ER) and HER2 pathways in different BC classes. Moreover, mTORC1 expression was assessed in 6 BC cell lines including ER+ and ER− cell lines with and without HER2 transfection. Immunohistochemistry was used to assess the expression of phospho (p) mTORC1 in a large (n = 1300) annotated BC series prepared as tissue microarray. Reverse phase protein array (RPPA) was used to assess its expression in the different BC cell lines. The expression of p-mTORC1 was cytoplasmic with moderate/high expression noted in 44 {\%} of BC. p-mTORC1 expression was associated with clinicopathological variables characteristic of good prognosis. Positive correlation with ER, ER-related proteins AKT, PI3K and luminal differentiation markers were observed in the whole series and in the ER+HER2− subgroup. Association with HER2 was mainly observed in the ER-negative class. RPPA indicated that p-mTORC1 expression was mainly related to ER expression and with better outcome in the Akt positive tumours. p-mTORC1 is associated with good prognostic features. Its expression is related to ER and ER related proteins in addition to AKT and PI3K. Its relation with HER2 expression is mainly seen in the absence of ER expression.",
keywords = "Breast cancer, Immunohistochemistry, mTORC1, pi3k pathway",
author = "Jerjees, {Dena A.} and Negm, {Ola H.} and Alabdullah, {M. Layth} and Sameer Mirza and Methaq Alkaabi and Hameed, {Mohamed R.} and Rezvan Abduljabbar and Abir Muftah and Nolan, {Chris C.} and Green, {Andrew R.} and Tighe, {Patrick J.} and Vimla Band and Ellis, {Ian O.} and Rakha, {Emad A.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/s10549-015-3308-4",
language = "English (US)",
volume = "150",
pages = "91--103",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer

T2 - the impact of oestrogen receptor and HER2 pathways

AU - Jerjees, Dena A.

AU - Negm, Ola H.

AU - Alabdullah, M. Layth

AU - Mirza, Sameer

AU - Alkaabi, Methaq

AU - Hameed, Mohamed R.

AU - Abduljabbar, Rezvan

AU - Muftah, Abir

AU - Nolan, Chris C.

AU - Green, Andrew R.

AU - Tighe, Patrick J.

AU - Band, Vimla

AU - Ellis, Ian O.

AU - Rakha, Emad A.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - The mammalian target of rapamycin complex 1 (mTORC1) is a downstream of the PI3K/Akt pathway which affects cancer development. mTORC1 has many downstream signalling effectors that can enhance different cellular responses. This study aims to investigate the expression of mTORC1 in breast cancer (BC) and correlate it with key clinicopathological and molecular features of BC especially to proteins related to oestrogen receptor (ER) and HER2 pathways in different BC classes. Moreover, mTORC1 expression was assessed in 6 BC cell lines including ER+ and ER− cell lines with and without HER2 transfection. Immunohistochemistry was used to assess the expression of phospho (p) mTORC1 in a large (n = 1300) annotated BC series prepared as tissue microarray. Reverse phase protein array (RPPA) was used to assess its expression in the different BC cell lines. The expression of p-mTORC1 was cytoplasmic with moderate/high expression noted in 44 % of BC. p-mTORC1 expression was associated with clinicopathological variables characteristic of good prognosis. Positive correlation with ER, ER-related proteins AKT, PI3K and luminal differentiation markers were observed in the whole series and in the ER+HER2− subgroup. Association with HER2 was mainly observed in the ER-negative class. RPPA indicated that p-mTORC1 expression was mainly related to ER expression and with better outcome in the Akt positive tumours. p-mTORC1 is associated with good prognostic features. Its expression is related to ER and ER related proteins in addition to AKT and PI3K. Its relation with HER2 expression is mainly seen in the absence of ER expression.

AB - The mammalian target of rapamycin complex 1 (mTORC1) is a downstream of the PI3K/Akt pathway which affects cancer development. mTORC1 has many downstream signalling effectors that can enhance different cellular responses. This study aims to investigate the expression of mTORC1 in breast cancer (BC) and correlate it with key clinicopathological and molecular features of BC especially to proteins related to oestrogen receptor (ER) and HER2 pathways in different BC classes. Moreover, mTORC1 expression was assessed in 6 BC cell lines including ER+ and ER− cell lines with and without HER2 transfection. Immunohistochemistry was used to assess the expression of phospho (p) mTORC1 in a large (n = 1300) annotated BC series prepared as tissue microarray. Reverse phase protein array (RPPA) was used to assess its expression in the different BC cell lines. The expression of p-mTORC1 was cytoplasmic with moderate/high expression noted in 44 % of BC. p-mTORC1 expression was associated with clinicopathological variables characteristic of good prognosis. Positive correlation with ER, ER-related proteins AKT, PI3K and luminal differentiation markers were observed in the whole series and in the ER+HER2− subgroup. Association with HER2 was mainly observed in the ER-negative class. RPPA indicated that p-mTORC1 expression was mainly related to ER expression and with better outcome in the Akt positive tumours. p-mTORC1 is associated with good prognostic features. Its expression is related to ER and ER related proteins in addition to AKT and PI3K. Its relation with HER2 expression is mainly seen in the absence of ER expression.

KW - Breast cancer

KW - Immunohistochemistry

KW - mTORC1

KW - pi3k pathway

UR - http://www.scopus.com/inward/record.url?scp=84925521905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925521905&partnerID=8YFLogxK

U2 - 10.1007/s10549-015-3308-4

DO - 10.1007/s10549-015-3308-4

M3 - Article

VL - 150

SP - 91

EP - 103

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -